US OptionsDetailed Quotes
CGEN241220P5000
- 2.80
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
2.80Open2.80Pre Close0 Volume10 Open Interest5.00Strike Price0.00Turnover0.00%IV-43.79%PremiumDec 20, 2024Expiry Date3.47Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.44Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Compugen Stock Discussion
Sign in to post a comment
$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
25
7
7
$Compugen (CGEN.US)$
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.
The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.
The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...
1
$Compugen (CGEN.US)$ 🤩
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.
$Compugen (CGEN.US)$ fk entered very early! now no option to hold at lesast 2 week or more !
$Compugen (CGEN.US)$ 👀looks good i n game 🎲
Michelle Mahler's appointment as Chief Medical Officer is a positive step for Compugen, thanks to her vast clinical development experience. Her leadership in the COM503 Phase 1 study and future role in advancing COM701, COM902, and COM503 are anticipated to significantly boost the company's clinical development strategy.
$Compugen (CGEN.US)$ can go up today?
$Compugen (CGEN.US)$ come on get up there so I can sell some calls lol
7
’s close now or forever hold your peace!!
$Compugen (CGEN.US)$ this stock can move up , dont worry
1
4
No comment yet
AddiBee0925 : Hey Jag. Just a heads up. If all goes as planned, the launch for SIDU and SpaceX is on the schedule for this Friday on the 20th. I wouldn't think that it would be rescheduled so soon to the launch, at least no report has said otherwise.
Jaguar8 OP AddiBee0925 : Yes. But there might be a build up of the price before the launch just like LUNR. Hopefully it goes well.
AddiBee0925 Jaguar8 OP : yeah I'm thinking the same
Jaguar8 OP browny_440 : TNXP will be good if FDA releases decision soon
72306783 : I would like to ask, what signals or standards do you use to start building positions? I am still learning... Thank you very much for your Share
View more comments...